KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Intangibles (2018 - 2022)

Esperion Therapeutics (ESPR) has disclosed Intangibles for 5 consecutive years, with $56000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Intangibles changed 0.0% year-over-year to $56000.0, compared with a TTM value of $56000.0 through Dec 2022, changed 0.0%, and an annual FY2022 reading of $56000.0, changed 0.0% over the prior year.
  • Intangibles was $56000.0 for Q4 2022 at Esperion Therapeutics, roughly flat from $56000.0 in the prior quarter.
  • Across five years, Intangibles topped out at $56000.0 in Q1 2018 and bottomed at $56000.0 in Q1 2018.
  • Average Intangibles over 5 years is $56000.0, with a median of $56000.0 recorded in 2018.
  • Peak annual rise in Intangibles hit 0.0% in 2019, while the deepest fall reached 0.0% in 2019.
  • Year by year, Intangibles stood at $56000.0 in 2018, then changed by 0.0% to $56000.0 in 2019, then changed by 0.0% to $56000.0 in 2020, then changed by 0.0% to $56000.0 in 2021, then changed by 0.0% to $56000.0 in 2022.
  • Business Quant data shows Intangibles for ESPR at $56000.0 in Q4 2022, $56000.0 in Q4 2021, and $56000.0 in Q4 2020.